Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia

Livedoid Vasculitis Clinical Trial

Official title:

Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05878327
• Other study ID #: KEK-ZH-Nr. 2013-0301
• Status: Completed
• Start date: August 2013
• Est. completion date: June 2015

Study information

• Verified date: May 2023
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia.

Description:

A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. The presence of Livedoid vasculopathy must be confirmed by a histologic specimen. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia. The presence of a history of smoking and thrombophilia is compared to the general Swiss population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 85 Years

Eligibility

Inclusion Criteria:

• History of livedoid vasculopathy

Exclusion Criteria:

• Diagnosis was not proved by biopsy specimen

• A different reason than livedoid vasculopathy has been found for the symptoms of the patient

• No informed consent by the patient

Related Conditions & MeSH terms

• Livedoid Vasculitis
• Livedoid Vasculopathy
• Thrombophilia
• Vasculitis

Intervention

Other:
• Thrombophilia screening
No intervention. Blood is drawn for analysis.

Locations

Country	Name	City	State
Switzerland	University hospital of Basel	Basel
Switzerland	University hospital of Bern	Bern
Switzerland	University hospital Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Smoking history: Patients will be asked if they currently smoke or if they are former smokers. If one of both items is yes, it means a positive answer.	The primary endpoint is the comparison of a positive smoking history and other cardiovascular risk factors of patients with livedoid vasculopathy with the Swiss general population.	22 months
Secondary	Thrombophilia screening: the following parameters will be determined in every participant: Factor V Leiden, Prothrombin 20210; Protein C, Protein S, Antithrombin III, Beta 2 Glykoprotein 1, Lupus Antikoagulans	The secondary endpoint is the search for thrombophilia in patients with livedoid vasculopathy.	22 months